心脏手术患者夜间输注右美托咪定预防术后谵妄:一项实用性、随机、双盲、安慰剂对照试验
该研究为实用性、多中心、双盲、安慰剂对照试验,2019年1月至2021年7月纳入≥65岁择期心脏手术成人患者,随机1:1分为右美托咪定组与安慰剂组,手术当晚起每晚20:00至次日8:00输注,在ICU期间每晚给药,最长7天。主要终点为术后7天内谵妄发生率,两组无显著差异(12.6% vs 12.4%,p=0.97)。右美托咪定组低血压事件显著更多(7.3% vs 0.6%,p<0.01)。3个月时功能结局(Short-form 36、认知失败问卷、PCL-5)两组相当。
要点
- 择期心脏手术后夜间输注右美托咪定未降低术后7天内谵妄发生率(12.6% vs 12.4%,p=0.97)。
- 右美托咪定组低血压事件显著多于安慰剂组(7.3% vs 0.6%,p<0.01)。
- 3个月时功能结局(Short-form 36、认知失败问卷、PCL-5)两组相当。
- 给药方案为手术当晚起每晚20:00至次日8:00输注,ICU期间每晚给药,最长7天。
适用人群与场景
- 年龄65岁及以上、需择期心脏手术的成人患者。
处置流程与药物剂量
- 右美托咪定或匹配安慰剂于手术当晚开始,每晚20:00至次日8:00输注,在ICU期间每晚给药,最长7天。
研究设计与关键结果
- 研究类型:实用性、多中心、随机、双盲、安慰剂对照试验,2019年1月至2021年7月开展;348例提供知情同意,333例随机化,331例接受手术并纳入分析(右美托咪定组165例,安慰剂组166例)。
- 主要终点:术后7天内谵妄发生率两组无显著差异(12.6% vs 12.4%,p=0.97)。
- 安全性:右美托咪定组低血压事件显著更多(7.3% vs 0.6%,p<0.01)。
- 3个月功能结局(Short-form 36、认知失败问卷、PCL-5)两组相当。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于≥65岁择期心脏手术后患者,夜间输注右美托咪定未能降低术后谵妄发生率,且低血压事件更多(7.3% vs 0.6%,p<0.01)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: After cardiac surgery, post-operative delirium (PoD) is acknowledged to have a significant negative impact on patient outcome. To date, there is no valuable and specific treatment for PoD. Critically ill patients often suffer from poor sleep condition. There is an association between delirium and sleep quality after cardiac surgery. This study aimed to establish whether promoting sleep using an overnight infusion of dexmedetomidine reduces the incidence of delirium after cardiac surgery.
METHODS: Randomized, pragmatic, multicentre, double-blind, placebo controlled trial from January 2019 to July 2021. All adult patients aged 65 years or older requiring elective cardiac surgery were randomly assigned 1:1 either to the dexmedetomidine group or the placebo group on the day of surgery. Dexmedetomidine or matched placebo infusion was started the night after surgery from 8 pm to 8 am and administered every night while the patient remained in ICU, or for a maximum of 7 days. Primary outcome was the occurrence of postoperative delirium (PoD) within the 7 days after surgery.
RESULTS: A total of 348 patients provided informed consent, of whom 333 were randomized: 331 patients underwent surgery and were analysed (165 assigned to dexmedetomidine and 166 assigned to placebo). The incidence of PoD was not significantly different between the two groups (12.6% vs. 12.4%, p = 0.97). Patients treated with dexmedetomidine had significantly more hypotensive events (7.3% vs 0.6%; p < 0.01). At 3 months, functional outcomes (Short-form 36, Cognitive failure questionnaire, PCL-5) were comparable between the two groups.
CONCLUSION: In patients recovering from an elective cardiac surgery, an overnight infusion of dexmedetomidine did not decrease postoperative delirium. Trial registration This trial was registered on ClinicalTrials.gov (number: NCT03477344; date: 26th March 2018).
参考来源
- Huet O, Gargadennec T, Oilleau JF, et al. Prevention of post-operative delirium using an overnight infusion of dexmedetomidine in patients undergoing cardiac surgery: a pragmatic, randomized, double-blind, placebo-controlled trial. Crit Care. 2024. PMID: 38419119. doi:10.1186/s13054-024-04842-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。